Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EXI1.F
- Price
- -
- Stock movement up
- +0.46 (0.32%)
- Company name
- Exchange
- (F ,
- Currency
- EUR )
- Market cap
- -
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 3.41%
- 3 year return
- 6.52%
- 5 year return
- 8.35%
- 10 year return
- 6.02%
Last updated: 2025-09-02
DIVIDENDS
EXI1.F does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| EXI1.F | S&P500 | |
| Current price drop from All-time high | -6.63% | - |
| Highest price drop | -50.49% | -56.47% |
| Date of highest drop | 12 Mar 2003 | 9 Mar 2009 |
| Avg drop from high | -12.96% | -10.99% |
| Avg time to new high | 21 days | 12 days |
| Max time to new high | 1438 days | 1805 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Mid-cap
Description
Employees
Investor relations
-
SEC filings
CEO
Country
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The cider brand has added a high-contrast NaviLens QR code to its cans.
September 9, 2025
BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty
September 9, 2025
Temenos also the winner for Bank Deposit Transformation with Credem and listed in the 2025 IDC FinTech Rankings Top 25GRAND-LANCY, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), ...
September 9, 2025
The Management Board of Artea Bankas has approved changes to the management and organizational structure. The Management Board has received a notice from board member Mindaugas Rudys regarding his res...
September 9, 2025
Novartis agreed to buy Tourmaline Bio in a roughly $1.4 billion-dollar deal that boosts its cardiovascular drug pipeline with access to the targeted therapy drug pacibekitug. The Swiss pharmaceuti...
September 9, 2025
Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmali...
September 9, 2025